Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06016725
Other study ID # OSU-22329
Secondary ID NCI-2023-04622R2
Status Recruiting
Phase N/A
First received
Last updated
Start date August 28, 2023
Est. completion date May 15, 2025

Study information

Verified date January 2024
Source Ohio State University Comprehensive Cancer Center
Contact The Ohio State Comprehensive Cancer Center
Phone 800-293-5066
Email OSUCCCClinicaltrials@osumc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial tests the feasibility, acceptability, and preliminary effectiveness of online dietary and resistance training to improve physical function in older (greater than or equal to 65-years old) cancer survivors. Declines in adequate protein and calorie intake results in faster loss of muscle mass and physical functioning in older adults. A novel approach to improving physical function in older cancer survivors (OCS) is to utilize online, tailored education and counseling from registered dietitians and exercise scientists, to improve dietary intake (protein intake, diet quality) and participation in resistance exercise. The purpose of this study is to help researchers learn whether an online dietary and resistance training intervention improves diet, exercise, physical function, and health outcomes in OCS.


Description:

PRIMARY OBJECTIVES: I. Determine the feasibility and acceptability of implementing a 12-week online dietary and resistance training randomized trial with 70 older cancer survivors. II. Examine the preliminary efficacy of this 12-week online dietary and resistance training intervention with the intervention participants. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients participate in online nutritional counseling over 30 minutes in weeks 1, 3, 5, 7, 9, and 11, and participate in online resistance training sessions weekly over 30 minutes in weeks 1-6 and biweekly at weeks 8, 10, and 12. Patients also receive educational materials at baseline. ARM 2: Patients receive educational materials at baseline. After completion of study intervention, patients are followed up at 3 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date May 15, 2025
Est. primary completion date August 1, 2024
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - >= 65 years of age - A primary diagnosis of stage I-III breast, colorectal, and prostate cancer - Completion of primary curative treatment - Reported at least 1 physical function limitation on the RAND-36 Physical Function Subscale (PFSS) ("limited a little", "limited a lot") - No evidence of progressive disease or second cancers - Community-dwelling - Able to provide consent Exclusion Criteria: - Currently receive cancer treatment (e.g., chemotherapy, radiation) - Have liver and/or renal disease limiting their protein intake - Are under the care of a Registered Dietician (RD)/nutritionist - Participating in other diet/exercise interventions - Consume protein supplements - Have contraindications to unsupervised exercise (e.g., walker/wheelchair use)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exercise Intervention
Participate in online resistance training sessions
Informational Intervention
Given educational materials
Nutritional Assessment
Participate in online nutritional counseling
Physical Performance Testing
Ancillary studies
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States Ohio State University Comprehensive Cancer Center Columbus Ohio

Sponsors (2)

Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Physical function Measured by the Short Physical Performance Battery (SPPB) score. Efficacy will be based on 12 weeks. The SPPB score is a continuous variable, collected as the total score ranging from 0-12. Group differences in SPPB scores over the time will be tested using repeated measures analysis of variance. Using the planned contrasts command, we will investigate the changes in SPPB scores within each group, and between the intervention and control groups at end-of-study. Descriptive statistics and frequency distributions will be used to characterize the sample. To examine the effect of the intervention on the changes in physical function, a linear mixed effect model will be adopted. Up to 12 weeks post study completion
Secondary Satisfaction of the delivery method and information provided by nutrition and exercise counseling sessions Percentage of participant satisfaction ("satisfied" and "very satisfied") measured by a 5-item Likert-scale questionnaire At 12 weeks
Secondary Study accrual rate Will be calculated by dividing the number of potential participants that passed screening by the total number of participants started in the study after appropriate informed consent procedures. Up to 9 months
Secondary Study retention rate Will be calculated by dividing the total number of participants initiated by total number of participants in the study. Retention goal for this trial is 80%. If 80% (56/70) of participants are retained at end-of-study, the retention goal for this trial will be achieved. Overall retention rates and associated 95% confidence intervals will be reported. At baseline and 12 weeks
Secondary Study adherence rate Participants will be determined to be adherent if they attend >= 80% of the intervention sessions (in-person meetings with study staff and online intervention sessions). Overall adherence rates and associated 95% confidence intervals will be reported. At baseline, 12 weeks, and 3-month follow-up
Secondary Muscle strength Handgrip strength will be measured in both hands using a hydraulic grip strength dynamometer. Change in participant outcome measures from baseline to end-of-study will be assessed in kilograms at the baseline and end of study visits. At baseline, 12 weeks, and 3-month follow-up
Secondary Dietary quality and protein intake Protein intake and dietary quality will be assessed by the National Cancer Institute's Diet History Questionnaire III using the Healthy Eating Index score ranging 0-100, with higher scores meaning higher diet quality. Change in participant outcome measures from baseline to end-of-study will be assessed using the Healthy Eating Index score. At baseline and 12 weeks
Secondary Resistance exercises Self-reported resistance exercise will be assessed using the revised version of The Godin-Shephard Leisure-Time Exercise Questionnaire modified to specifically capture self-reported resistance exercise participation, reported in frequency of days per week and duration in minutes. Change in participant outcome measures from baseline to end-of-study will be assessed using the reported frequency of days per week and duration in minutes. At baseline and 12 weeks
Secondary Health-related quality of life (HRQoL) physical and emotional health scores RAND-36 Health Status Measure is comprised of 36 items which automatically create 8 subscales assessing multiple aspects of HRQoL. Physical and mental component summaries are created. All scores range from 0-100, with 100 as the highest. Change in participant outcome measures from baseline to end-of-study will be assessed using the RAND-36 Health Status Measure score. At baseline and 12 weeks
Secondary Self-efficacy for improving diet quality and increasing resistance training Self-efficacy will be measured via a 0-10 confidence scale rating the confidence of making exercise and diet changes, with 0 meaning not confident, 10 meaning very confident. Change in participant outcome measures from baseline to end-of-study will be assessed using the confidence scale rating. At baseline and 12 weeks
Secondary Technology competency The 8-item eHealth Literacy Scale will measure knowledge, comfort, and perceived skills of engaging in eHealth at baseline and end-of-study. A 5-point Likert scale will be used. Change in participant outcome measures from baseline to end-of-study will be assessed using the 5-point Likert scale score. At baseline and 12 weeks
Secondary Anthropometry body weight in kilograms Change in participant outcome measure body weight from baseline to end-of-study will be assessed using body weight in kilograms. At baseline and 12 weeks
Secondary Anthropometry height in inches Change in participant outcome measure height from baseline to end-of-study will be assessed using height in inches. At baseline and 12 weeks
Secondary Anthropometry measuring waist circumference in centimeters Change in participant outcome measure waist circumference from baseline to end-of-study will be assessed using waist circumference in centimeters. At baseline and 12 weeks
See also
  Status Clinical Trial Phase
Suspended NCT05673200 - Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer Phase 1
Active, not recruiting NCT03218826 - PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Completed NCT04535323 - Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer Phase 1
Recruiting NCT05464810 - Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer Early Phase 1
Active, not recruiting NCT04249622 - Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer Phase 2
Withdrawn NCT03666819 - Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy Phase 2
Not yet recruiting NCT05930483 - Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors N/A
Recruiting NCT04862585 - Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel Phase 2/Phase 3
Withdrawn NCT05967286 - Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial Phase 2
Recruiting NCT04593277 - Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study N/A
Active, not recruiting NCT05086731 - Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer N/A
Recruiting NCT05368428 - Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer N/A
Recruiting NCT04673448 - Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Not yet recruiting NCT05539365 - Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer Phase 2
Active, not recruiting NCT04086875 - A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer N/A
Completed NCT00507923 - Tibetan Yoga in Improving Fatigue and Sleep in Participants With Stage I-III Breast Cancer N/A
Recruiting NCT06058377 - Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer Phase 3
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Recruiting NCT05455658 - STEMVAC in Patients With Early Stage Triple Negative Breast Cancer Phase 2
Recruiting NCT05674578 - Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors N/A

External Links